PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32683508-5	2021	Flow cytometry evaluation of the expression of mMICA after treatment with various candidate drugs identified leukotriene receptor antagonists as potential ADAM9 inhibitors.	Leukotrienes	109-120	ADAM metallopeptidase domain 9	Homo sapiens	155-160	
32683508-6	2021	Furthermore, leukotriene receptor antagonists alone or in combination with regorafenib upregulated mMICA, which was in turn downregulated by leukotriene C4 and D4 via ADAM9 function.	Leukotrienes	13-24	ADAM metallopeptidase domain 9	Homo sapiens	167-172	
32683508-6	2021	Furthermore, leukotriene receptor antagonists alone or in combination with regorafenib upregulated mMICA, which was in turn downregulated by leukotriene C4 and D4 via ADAM9 function.	Leukotrienes	141-152	ADAM metallopeptidase domain 9	Homo sapiens	167-172	
32683508-7	2021	Our study demonstrates that leukotriene receptor antagonists could be developed as novel drugs for immunological control and suppression of ADAM9 in HCC.	Leukotrienes	28-39	ADAM metallopeptidase domain 9	Homo sapiens	140-145